Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Enzon Pharmaceuticals, a biopharmaceutical company, has announced the discontinuation of the current recombinant human Mannose-Binding Lectin or rhMBL clinical program, as it did not meet the criteria established for its continued development.
Subscribe to our email newsletter
Jeffrey Buchalter, chairman and CEO of Enzon, said: “As we previously demonstrated, Enzon maintains high standards for developing its important and novel compounds. While it did not achieve the strict criteria we set forth for this program, MBL may still be a very important target in managing infectious complications.”
In 2005 Enzon acquired the rights to rhMBL from the Danish biotech company NatImmune. Enzon has studied rhMBL in Phase Ib studies for the prevention of severe infections in individuals with multiple myeloma or undergoing liver transplant with deficient levels of MBL.